A detailed history of Y Intercept (Hong Kong) LTD transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Y Intercept (Hong Kong) LTD holds 7,947 shares of SRPT stock, worth $830,779. This represents 0.06% of its overall portfolio holdings.

Number of Shares
7,947
Previous 37,756 78.95%
Holding current value
$830,779
Previous $5.97 Million 83.37%
% of portfolio
0.06%
Previous 0.34%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

SELL
$124.33 - $156.75 $3.71 Million - $4.67 Million
-29,809 Reduced 78.95%
7,947 $992,000
Q2 2024

Aug 14, 2024

BUY
$113.33 - $163.85 $3.24 Million - $4.68 Million
28,568 Added 310.93%
37,756 $5.97 Million
Q1 2024

May 10, 2024

BUY
$93.7 - $141.53 $860,915 - $1.3 Million
9,188 New
9,188 $1.19 Million
Q1 2023

May 09, 2023

SELL
$117.53 - $155.99 $301,699 - $400,426
-2,567 Reduced 15.56%
13,926 $1.92 Million
Q4 2022

Feb 14, 2023

BUY
$100.86 - $132.13 $658,716 - $862,941
6,531 Added 65.56%
16,493 $2.14 Million
Q2 2022

Aug 08, 2022

BUY
$62.69 - $88.44 $370,936 - $523,299
5,917 Added 146.28%
9,962 $747,000
Q1 2022

May 16, 2022

SELL
$63.15 - $90.42 $256,136 - $366,743
-4,056 Reduced 50.07%
4,045 $316,000
Q4 2021

Feb 14, 2022

SELL
$77.28 - $99.42 $46,136 - $59,353
-597 Reduced 6.86%
8,101 $729,000
Q3 2021

Nov 15, 2021

BUY
$65.97 - $92.48 $573,807 - $804,391
8,698 New
8,698 $804,000
Q2 2021

Aug 12, 2021

SELL
$69.38 - $86.75 $456,867 - $571,248
-6,585 Closed
0 $0
Q1 2021

May 12, 2021

BUY
$72.25 - $168.95 $180,263 - $421,530
2,495 Added 61.0%
6,585 $481,000
Q4 2020

Feb 05, 2021

BUY
$125.56 - $178.74 $513,540 - $731,046
4,090 New
4,090 $702,000

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $9.15B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Y Intercept (Hong Kong) LTD Portfolio

Follow Y Intercept (Hong Kong) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Y Intercept (Hong Kong) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Y Intercept (Hong Kong) LTD with notifications on news.